移植后淋巴组织增生性疾病在儿童扁桃体腺样体肥大中的研究进展  

Research progress of post-transplantation lymphoproliferative disease in children with adenotonsillar hypertrophy

作　　者：张涵 孙婷[1] 王延飞[1] 张肖林[1] 车娟[1] Zhang Han;Sun Ting;Wang Yanfei;Zhang Xiaolin;Che Juan(Department of Otolaryngology Head and Neck Surgery,Binzhou Medical University Hospital,Binzhou 256603,China)

机构地区：[1]滨州医学院附属医院耳鼻咽喉头颈外科,滨州256603

出　　处：《国际医药卫生导报》2025年第5期752-757,共6页International Medicine and Health Guidance News

基　　金：山东省医药卫生科技发展计划(2019WSB30010)。

摘　　要：移植后淋巴组织增生性疾病(PTLD)为儿科常见疾病,具有异质性的继发性恶性肿瘤。儿童发病率高于成人,病死率为20%。PTLD常首发于头颈部Waldeyer环,表现为扁桃体腺样体肥大、扁桃体炎或颈部淋巴结肿大。儿童扁桃体腺样体肥大是耳鼻咽喉科常见疾病,移植后儿童出现扁桃体腺样体肥大,应警惕PTLD。本文综述PTLD在扁桃体腺样体肥大中的流行病学、发病机制、临床表现、诊断及治疗研究进展,旨在早期识别诊断和治疗PTLD,改善预后。Post-transplantation lymphoproliferative disease(PTLD)is a prevalent and diverse form of secondary malignancy observed in pediatric patients.The incidence of PTLD is higher in children than in adults,with a mortality rate reaching up to 20%.PTLD typically originates within the Waldeyer ring of the head and neck,presenting as adenotonsillar hypertrophy,tonsillitis,or cervical lymph node enlargement.Adenotonsillar hypertrophy in children is a common disease in otorhinolaryngology;when adenotonsillar hypertrophy occurs in post-transplant children,the possibility of PTLD should be alerted.Hence,this article comprehensively reviews the current research progress on the epidemiology,pathogenesis,clinical manifestations,diagnosis,and treatment of PTLD in children with adenotonsillar hypertrophy,aiming to enhance early identification,accurate diagnosis,and effective treatment of PTLD in children with adenotonsillar hypertrophy after their first transplantation,and improve the prognosis.

关 键 词：移植后淋巴组织增生性疾病 器官移植 扁桃体腺样体肥大 EB病毒 儿童 进展 

分 类 号：R73[医药卫生—肿瘤]